T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan Inc
AGN
|
+$1.3B |
| 2 |
American Airlines Group
AAL
|
+$853M |
| 3 |
Intuitive Surgical
ISRG
|
+$816M |
| 4 |
Morgan Stanley
MS
|
+$681M |
| 5 |
Wynn Resorts
WYNN
|
+$622M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Procter & Gamble
PG
|
+$1.4B |
| 2 |
eBay
EBAY
|
+$763M |
| 3 |
DISCK
Discovery, Inc. Series C Common Stock
DISCK
|
+$760M |
| 4 |
Broadcom
AVGO
|
+$757M |
| 5 |
US Bancorp
USB
|
+$686M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 16.64% |
| 2 | Consumer Discretionary | 13.46% |
| 3 | Financials | 12.79% |
| 4 | Industrials | 12.13% |
| 5 | Technology | 9.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
526
Teledyne Technologies
TDY
$31.2B
| $143M | 0.03% |
1,476,773
+15,020
| +1% | +$1.44M |
|
527
Lockheed Martin
LMT
$138B
| $143M | 0.03% |
890,074
+17,107
| +2% | +$2.78M |
|
528
Aon
AON
$75.7B
| $143M | 0.03% |
1,587,843
+69,240
| +5% | +$5.99M |
|
|
CAM
529
DELISTED
CAMERON INTERNATIONAL CORPORATION
CAM
| $143M | 0.03% |
2,112,572
-845,761
| -29% | -$54.5M |
|
530
Carpenter Technology
CRS
$26.6B
| $143M | 0.03% |
2,261,377
-112,795
| -5% | -$7.16M |
|
531
Medtronic
MDT
$116B
| $143M | 0.03% |
2,238,755
+38,401
| +2% | +$2.33M |
|
532
Manitowoc
MTW
$753M
| $143M | 0.03% |
4,792,373
-1,624,864
| -25% | -$43.2M |
|
|
CRR
533
DELISTED
Carbo Ceramics Inc.
CRR
| $142M | 0.03% |
922,965
+277,391
| +43% | +$38.2M |
|
534
International Flavors & Fragrances
IFF
$21.4B
| $142M | 0.03% |
1,363,536
-7,387
| -0.5% | -$727K |
|
535
Canadian Natural Resources
CNQ
$98.1B
| $142M | 0.03% |
+6,405,584
| New | +$128M |
|
|
HOLX
536
DELISTED
Hologic
HOLX
| $142M | 0.03% |
5,593,031
+2,451,233
| +78% | +$57.3M |
|
537
Alaska Air
ALK
$5.3B
| $142M | 0.03% |
2,979,916
-59,640
| -2% | -$2.84M |
|
|
CYT
538
DELISTED
CYTEC INDS INC
CYT
| $140M | 0.03% |
2,659,920
+1,802,622
| +210% | +$89.1M |
|
539
Constellium
CSTM
$3.95B
| $140M | 0.03% |
4,363,598
-111,309
| -2% | -$3.35M |
|
|
CNL
540
DELISTED
CLECO CRP (HOLDING CO)
CNL
| $139M | 0.03% |
2,364,560
-6,550
| -0.3% | -$341K |
|
541
Cummins
CMI
$87B
| $139M | 0.03% |
903,407
-779,720
| -46% | -$118M |
|
542
Westamerica Bancorp
WABC
$1.39B
| $139M | 0.03% |
2,655,928
-2,600
| -0.1% | -$133K |
|
543
Flotek Industries
FTK
$1.25B
| $139M | 0.03% |
718,572
+8,499
| +1% | +$1.49M |
|
544
Tenaris
TS
$26.6B
| $137M | 0.03% |
2,907,328
+21,489
| +0.7% | +$965K |
|
545
Align Technology
ALGN
$12.5B
| $137M | 0.03% |
2,440,659
+1,652,995
| +210% | +$86M |
|
|
WCG
546
DELISTED
Wellcare Health Plans, Inc.
WCG
| $137M | 0.03% |
1,830,958
-434,990
| -19% | -$31M |
|
|
FNFG
547
DELISTED
FIRST NIAGARA FINANCIAL GROUP INC
FNFG
| $136M | 0.03% |
15,523,089
+816,805
| +6% | +$7.23M |
|
|
VTLE
548
DELISTED
Vital Energy
VTLE
| $135M | 0.03% |
218,368
-66,871
| -23% | -$37.9M |
|
549
Acadia Pharmaceuticals
ACAD
$4.89B
| $135M | 0.03% |
5,962,463
+3,178,943
| +114% | +$66.4M |
|
550
BioMarin Pharmaceuticals
BMRN
$13.3B
| $134M | 0.03% |
2,153,525
-146,424
| -6% | -$8.85M |
|
Similar funds
T. Rowe Price Associates's Q2 2014 Portfolio in Review
As of Q2 2014, T. Rowe Price Associates held 2,596 positions worth $463B, up 3.9% from $445B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
T. Rowe Price Associates's Q2 2014 filing shows 97 new, 1,091 increased, 793 reduced and 67 closed positions. Its largest new stake was Teva Pharmaceuticals: 4,638,481 shares worth $243M. The largest sale was Procter & Gamble, an estimated $1.4B.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 16% a quarter earlier, followed by Consumer Discretionary and Financials.
- T. Rowe Price Associates's largest Q2 2014 buy was Teva Pharmaceuticals: 4,638,481 shares worth $243M.
- T. Rowe Price Associates added most to Allergan Inc in Q2 2014, an estimated $1.3B increase.
- T. Rowe Price Associates's biggest Q2 2014 reduction was Procter & Gamble, cutting an estimated $1.4B.
- T. Rowe Price Associates fully exited Santander in Q2 2014, selling an estimated $134M.
- T. Rowe Price Associates's ten largest holdings make up 12% of its $463B portfolio in Q2 2014.
- T. Rowe Price Associates opened 97 new positions and closed 67 in Q2 2014.
- T. Rowe Price Associates's portfolio value rose 3.9% quarter-over-quarter to $463B.
Based on T. Rowe Price Associates's 13F filing for Q2 2014, filed 14 Aug 2014.